Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Zepbound achieved 47% greater relative weight loss vs. Wegovy, with an average loss of 20.2% compared to 13.7%. At 72 weeks, 31.6% of Zepbound users lost at least 25% body weight vs. 16.1% for ...

According to market research firm GlobalData on the 2nd (local time), Eli Lilly's obesity drug Zepbound is projected to quickly surpass Novo Nordisk's Wegovy in market share and dominate the ...

But a recent head-to-head trial comparing Zepbound vs. Wegovy provided new insights into their effectiveness, making the choice slightly clearer. The findings? Zepbound led to an average weight ...

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than rival Novo Nordisk’s NVO Wegovy in a first-ever head-to-head obesity ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday. NBC News ...

The medications are so common now, two-thirds of the clinic’s calls for insurance pre-authorizations are for the big three: ...

Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight compared to 16% of study participants who took Wegovy. Experts note that weight loss drugs can only be ...